HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma

PURPOSE: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used multi-omics approaches and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance. EXPERIMENTAL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Faião-Flores, Fernanda, Emmons, Michael F., Durante, Michael A., Kinose, Fumi, Saha, Biswarup, Fang, Bin, Koomen, John M., Chellappan, Srikumar, Maria-Engler, Silvya Stuchi, Rix, Uwe, Licht, Jonathan D., Harbour, J. William, Smalley, Keiran S.M.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6744978/
https://ncbi.nlm.nih.gov/pubmed/31227503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3382
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars